Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design

Future Oncology - Tập 16 Số 21 - Trang 1525-1536 - 2020
Robin Kate Kelley1,2, Jennifer Oliver3, Saswati Hazra3, Fawzi Benzaghou4, Thomas Yau5, Ann‐Lii Cheng6, Lorenza Rimassa7,8
1Fax: 415 353 9959
2UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA94143, USA
3Exelixis, Inc., Alameda, CA, USA
4Ipsen Bioscience, Inc., Cambridge, MA, USA
5University of Hong Kong, Hong Kong, China
6National Taiwan University, College of Medicine, Taipei, Taiwan
7Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
8Medical Oncology & Hematology Unit, Humanitas Cancer Center, Humanitas Clinical & Research Center, IRCCS, Rozzano, Milan, ItalyDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1186/s13046-019-1396-4

10.1093/annonc/mdz394.029

10.1200/JCO.19.01307

10.1056/NEJMoa1915745

10.1056/NEJMoa0708857

10.1016/S0140-6736(18)30207-1

10.1016/S0140-6736(16)32453-9

10.1056/NEJMoa1717002

10.1016/S1470-2045(18)30937-9

10.1038/s41591-018-0053-3

10.1056/NEJMoa1816047

10.1200/JCO.2018.36.6_suppl.515

10.1056/NEJMoa1816714

10.1158/1535-7163.MCT-11-0264

10.1200/JCO.2016.34.15_suppl.4534

10.1200/jco.2014.32.15_suppl.4501

10.1200/JCO.2020.38.4_suppl.478

Agarwal N , VaishampayanU, GreenMet al. Phase 1b study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose escalation stage. Ann. Oncol.29(Suppl. 8), Abstract 872P (2018).

10.1200/JCO.2019.37.7_suppl.TPS683

10.1016/S0140-6736(17)31046-2

10.1016/S1470-2045(18)30351-6

10.1038/nature14011

10.1200/JCO.2015.63.7421

10.1016/S0140-6736(19)30723-8

Lee M , RyooB-Y, HsuC-Het al. Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC). Ann. Oncol.30(Suppl. 5), Abstract LBA39 (2019).

10.1158/1535-7163.MCT-18-1399

10.1038/nature21349

10.1155/2012/492920

10.1038/ncomms12624

10.3389/fonc.2015.00202

10.3389/fonc.2014.00070

10.1111/imr.12522

10.1186/s12967-014-0294-y

10.1074/jbc.M114.612689

10.1016/j.immuni.2017.09.012

10.3390/biomedicines3010138

10.1038/ncomms13898

10.18632/oncotarget.21125

10.3390/cancers8100097

10.1038/nrc3847

10.1038/nature21676

10.1200/JCO.2016.34.15_suppl.1093

Verzoni E , FerroS, ProcopioGet al. Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pretreated metastatic renal cell carcinoma (mRCC) patients. Ann. Oncol.29(Suppl. 8), viii303–viii331 (2018).

10.1016/j.ejca.2008.10.026

10.1200/JCO.2017.75.1644

10.1007/s11136-011-9903-x

10.1200/JCO.2018.36.15_suppl.TPS4144

10.1200/JCO.2019.37.15_suppl.TPS4152

Thông tin
Thông tin xuất bản

Future Oncology

Tập 16 Số 21

1525-1536

Thông tin tác giả